1. Home
  2. SLDB

SLDB

Solid Biosciences Inc.

Logo Solid Biosciences Inc.

Health Care

Biotechnology: Biological Products (No Diagnostic Substances)

Nasdaq

as 04-22-2024 11:32am EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Solid Biosciences Inc is a life science company. It is engaged in the manufacturing of specialty and generic drugs. The company is involved in curing Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease predominantly affecting boys, with symptoms that usually manifest between three and five years of age. The company's pipeline products are the SB-001 and solid suit. The Company's singular focus is on developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases. The company has categorized its programs into corrective therapies, disease-modifying therapies, and assistive devices.

Founded: 2013 Country:
United States
United States
Employees: 88 City: CHARLESTOWN
Market Cap: 328.5M IPO Year: 2018
Target Price: $18.14 AVG Volume (30 days): 266.6K
Analyst Decision: Strong Buy Number of Analysts: 7
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -4.83 EPS Growth: N/A
52 Week Low/High: $1.81 - $15.05 Next Earning Date: 05-09-2024
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): 12.64%

Share on Social Networks:

Stock Insider Trading Activity of Solid Biosciences Inc. (SLDB)

Name Ticker Relationship Date Transaction Cost Per Share Shares Total Value Securities Owned After Transaction(s) SEC Form 4
PERCEPTIVE ADVISORS LLC SLDB Director10% Owner Jan 11 '24 Buy $5.53 3,410,713 $18,861,242.89 6,833,539 SEC Form 4